ERAS

Erasca, Inc. - Common Stock (ERAS)

About Erasca, Inc. - Common Stock (ERAS)

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Details

Daily high

$15.29

Daily low

$14.60

Price at open

$14.96

52 Week High

$24.28

52 Week Low

$1.75

Market cap

5.2B

Dividend yield

Volume

3.5M

Avg. volume

4.8M

P/E ratio

-15.47

Erasca, Inc. - Common Stock News